We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CC Sees Gains From Opteon Growth in Q2, Navigates Disruptions in TT
Read MoreHide Full Article
Key Takeaways
CC expects Q2 adjusted EBITDA of $215-$225M and positive free cash flow for the quarter.
TSS projects 25% sales and 40% EBITDA growth from strong Opteon demand under the AIM Act.
TT sees a 15% EBITDA drop from $15M higher costs in disruptions; APM EBITDA to rise 25% on cost strength.
The Chemours Company (CC - Free Report) updated its second-quarter 2025 outlook ending June 30. CC expects consolidated net sales for the second quarter to be at the high end of the original range, expecting a sequential mid-teens increase.
Thermal & Specialized Solutions (“TSS”) segment anticipates around a 25% sequential increase in net sales due to stronger demand for Opteon Refrigerants from the transition to low global warming potential refrigerants under the U.S. AIM Act. Based on higher demand, it also expects a sequential increase of roughly 40% in adjusted EBITDA.
In contrast to this, the Titanium Technologies (“TT”) segment projects a 15% sequential decline in its adjusted EBITDA. Overall net sales are expected to be in line with high single-digit growth expectations. The expected decline in adjusted EBITDA can be attributed to operational disruptions at its U.S. site that resulted in incremental costs of approximately $15 million in the second quarter from higher-cost ore feedstock to fulfill customer orders due to the rail line disruption. Other one-time operational disruptions are expected to cost approximately $10 million in the quarter.
Advanced Performance Materials (“APM”) segment’s net sales are predicted to be within the original expectations of low teens sequential growth, while adjusted EBITDA is expected to increase around 25% sequentially due to stronger overall cost performance.
CC’s focus on resolving legacy litigation, under the Strengthening the Long-Term pillar, is anticipated to result in a modestly higher expectation of corporate costs in connection with the ongoing New Jersey trial. Consolidated adjusted EBITDA is now expected to be in the range of $215 million to $225 million, with consolidated free cash flow projected to remain positive in the second quarter.
CC stock has lost 51.5% over the past year compared with the industry’s 24.7% decline.
Image Source: Zacks Investment Research
CC’s Zacks Rank & Key Picks
CC currently carries a Zacks Rank #5 (Strong Sell).
The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.67 per share, implying a 19.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $4.18 per share, indicating a 20.1% year-over-year rise.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM’s shares have gained 39.6% in the past year.
The Zacks Consensus Estimate for BCPC’s 2025 earnings is pegged at $5.15 per share, indicating a rise of 31% from year-ago levels. The company’s earnings beat the consensus estimate in two of the trailing four quarters while missing the rest. Its shares have gained 3.5% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CC Sees Gains From Opteon Growth in Q2, Navigates Disruptions in TT
Key Takeaways
The Chemours Company (CC - Free Report) updated its second-quarter 2025 outlook ending June 30. CC expects consolidated net sales for the second quarter to be at the high end of the original range, expecting a sequential mid-teens increase.
Thermal & Specialized Solutions (“TSS”) segment anticipates around a 25% sequential increase in net sales due to stronger demand for Opteon Refrigerants from the transition to low global warming potential refrigerants under the U.S. AIM Act. Based on higher demand, it also expects a sequential increase of roughly 40% in adjusted EBITDA.
In contrast to this, the Titanium Technologies (“TT”) segment projects a 15% sequential decline in its adjusted EBITDA. Overall net sales are expected to be in line with high single-digit growth expectations. The expected decline in adjusted EBITDA can be attributed to operational disruptions at its U.S. site that resulted in incremental costs of approximately $15 million in the second quarter from higher-cost ore feedstock to fulfill customer orders due to the rail line disruption. Other one-time operational disruptions are expected to cost approximately $10 million in the quarter.
Advanced Performance Materials (“APM”) segment’s net sales are predicted to be within the original expectations of low teens sequential growth, while adjusted EBITDA is expected to increase around 25% sequentially due to stronger overall cost performance.
CC’s focus on resolving legacy litigation, under the Strengthening the Long-Term pillar, is anticipated to result in a modestly higher expectation of corporate costs in connection with the ongoing New Jersey trial. Consolidated adjusted EBITDA is now expected to be in the range of $215 million to $225 million, with consolidated free cash flow projected to remain positive in the second quarter.
CC stock has lost 51.5% over the past year compared with the industry’s 24.7% decline.
Image Source: Zacks Investment Research
CC’s Zacks Rank & Key Picks
CC currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks in the Basic Materials space are Akzo Nobel N.V. (AKZOY - Free Report) , Newmont Corporation (NEM - Free Report) and Balchem Corporation (BCPC - Free Report) . While AKZOY and NEM currently sport a Zacks Rank #1 (Strong Buy), BCPC carries a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Akzo Nobel’s current-year earnings is pegged at $1.67 per share, implying a 19.3% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters while missing once.
The Zacks Consensus Estimate for NEM’s current-year earnings is pegged at $4.18 per share, indicating a 20.1% year-over-year rise.Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 32.41%. NEM’s shares have gained 39.6% in the past year.
The Zacks Consensus Estimate for BCPC’s 2025 earnings is pegged at $5.15 per share, indicating a rise of 31% from year-ago levels. The company’s earnings beat the consensus estimate in two of the trailing four quarters while missing the rest. Its shares have gained 3.5% in the past year.